BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

751 related articles for article (PubMed ID: 33581134)

  • 1. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
    Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
    Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.
    Costa B; Bendinelli S; Gabelloni P; Da Pozzo E; Daniele S; Scatena F; Vanacore R; Campiglia P; Bertamino A; Gomez-Monterrey I; Sorriento D; Del Giudice C; Iaccarino G; Novellino E; Martini C
    PLoS One; 2013; 8(8):e72281. PubMed ID: 23977270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells.
    Daniele S; Costa B; Zappelli E; Da Pozzo E; Sestito S; Nesi G; Campiglia P; Marinelli L; Novellino E; Rapposelli S; Martini C
    Sci Rep; 2015 Apr; 5():9956. PubMed ID: 25898313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner.
    Pham K; Luo D; Siemann DW; Law BK; Reynolds BA; Hothi P; Foltz G; Harrison JK
    Cancer Lett; 2015 Apr; 360(1):60-7. PubMed ID: 25676691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXCR4 increases in-vivo glioma perivascular invasion, and reduces radiation induced apoptosis: A genetic knockdown study.
    Yadav VN; Zamler D; Baker GJ; Kadiyala P; Erdreich-Epstein A; DeCarvalho AC; Mikkelsen T; Castro MG; Lowenstein PR
    Oncotarget; 2016 Dec; 7(50):83701-83719. PubMed ID: 27863376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
    Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
    Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3.
    Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J
    Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
    Xie X; He G; Siddik ZH
    Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas.
    Redjal N; Chan JA; Segal RA; Kung AL
    Clin Cancer Res; 2006 Nov; 12(22):6765-71. PubMed ID: 17121897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic drugs in combination with the CXCR4 antagonist AMD3100 as a potential treatment option for pediatric rhabdomyosarcoma.
    Regenbogen S; Stagno MJ; Schleicher S; Schilbach K; Bösmüller H; Fuchs J; Schmid E; Seitz G
    Int J Oncol; 2020 Jul; 57(1):289-300. PubMed ID: 32377699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
    Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
    J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation.
    Chen X; Tai L; Gao J; Qian J; Zhang M; Li B; Xie C; Lu L; Lu W; Lu W
    J Control Release; 2015 Nov; 218():29-35. PubMed ID: 26428461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A high-content small molecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like kinase 1.
    Danovi D; Folarin A; Gogolok S; Ender C; Elbatsh AM; Engström PG; Stricker SH; Gagrica S; Georgian A; Yu D; U KP; Harvey KJ; Ferretti P; Paddison PJ; Preston JE; Abbott NJ; Bertone P; Smith A; Pollard SM
    PLoS One; 2013; 8(10):e77053. PubMed ID: 24204733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action.
    Punganuru SR; Artula V; Zhao W; Rajaei M; Deokar H; Zhang R; Buolamwini JK; Srivenugopal KS; Wang W
    Cells; 2020 Jul; 9(7):. PubMed ID: 32630235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma.
    Barone A; Sengupta R; Warrington NM; Smith E; Wen PY; Brekken RA; Romagnoli B; Douglas G; Chevalier E; Bauer MP; Dembowsky K; Piwnica-Worms D; Rubin JB
    Oncotarget; 2014 Oct; 5(20):9811-22. PubMed ID: 25238146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long lasting MDM2/Translocator protein modulator: a new strategy for irreversible apoptosis of human glioblastoma cells.
    Daniele S; Barresi E; Zappelli E; Marinelli L; Novellino E; Da Settimo F; Taliani S; Trincavelli ML; Martini C
    Oncotarget; 2016 Feb; 7(7):7866-84. PubMed ID: 26761214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
    Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
    J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of glycolytic metabolism in glioblastoma cells by Pt3glc combinated with PI3K inhibitor via SIRT3-mediated mitochondrial and PI3K/Akt-MAPK pathway.
    Wang G; Fu XL; Wang JJ; Guan R; Sun Y; Tony To SS
    J Cell Physiol; 2019 May; 234(5):5888-5903. PubMed ID: 29336479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adult mouse subventricular zones stimulate glioblastoma stem cells specific invasion through CXCL12/CXCR4 signaling.
    Goffart N; Kroonen J; Di Valentin E; Dedobbeleer M; Denne A; Martinive P; Rogister B
    Neuro Oncol; 2015 Jan; 17(1):81-94. PubMed ID: 25085362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier.
    Kim M; Ma DJ; Calligaris D; Zhang S; Feathers RW; Vaubel RA; Meaux I; Mladek AC; Parrish KE; Jin F; Barriere C; Debussche L; Watters J; Tian S; Decker PA; Eckel-Passow JE; Kitange GJ; Johnson AJ; Parney IF; Anastasiadis PZ; Agar NYR; Elmquist WF; Sarkaria JN
    Mol Cancer Ther; 2018 Sep; 17(9):1893-1901. PubMed ID: 29970480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.